Replies to post #33897 on Humanigen Inc (HGENQ)

[cowtown jay]

I think the main reason Humanigen commissioned this study was to enable the FDA and customers to understand the proposed cost of $10,000 per treatment. When viewed in the context of what hospitalization costs are once a Covid patient progresses to IMV or death, the study demonstrates a clear cost savings to hospitals by administering lenz to prevent that progression. There may be thought that that may be more cost/benefit than risk/benefit associated, but I wouldn't agree. This is a net benefit.